The drug, Revolixys, was being evaluated against the anticoagulant
bivalirudin in patients undergoing percutaneous coronary
intervention, which is performed to open blocked coronary arteries
and restore blood flow to the heart tissue.
Regado's shares crashed in July after it was revealed that a data
safety monitoring board was reviewing the heart trial data.
The U.S. Food and Drug Administration also imposed a clinical hold
on the trial.
(Reporting by Natalie Grover in Bangalore; Editing by Joyjeet Das)
[to top of second column]
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.